We’re looking forward to sharing encouraging Phase 2 data in patients with Alzheimer’s disease with our proprietary combination treatment (CST-2032/CST-107) at the Clinical Trials in Alzheimer's Disease conference this week in Boston. Dr. John Harrison, a cognition expert and associate professor at the Alzheimer Center at Amsterdam’s VU medical center, will present our late-breaking abstract (#PO34):?“Combination Treatment of a Novel β2-Adrenoceptor Agonist, CST-2032, and Nadolol Improves Cognitive Measures in Patients with Alzheimer’s Disease. #CTAD #Alzheimers #Phase2 #dementia #MCI #CTAD# See our website for the poster - www.curasen.com/news.
Education Development Director at Touch Independent Medical Education
1 年This is exciting to see, congratulations!